Clinical Trial Identifier: NCT06329141
Status: Recruiting
Sponsor: Glaceum Inc.
Phase: Phase IIa
Intervention: Vutiglabridin vs placebo
This is a randomized, double-blind, placebo-controlled, parallel groups Phase IIa clinical trial to assess the efficacy and safety of Vutiglabridin in early Parkinson's Disease patients.
Glaceum Inc. has evaluated the safety, tolerability, and pharmacokinetic/pharmacodynamic properties of Vutiglabridin in healthy subjects through Phase 1 trials. This Phase IIa trial represents the transition to patient evaluation.
While the specific mechanism of Vutiglabridin is not detailed in the trial registration, the sponsor (Glaceum) is developing this compound for early Parkinson's Disease, likely targeting neuroprotection or symptomatic relief.
The trial is being conducted at multiple sites in South Korea: